1. Home
  2. NOTV vs BCDA Comparison

NOTV vs BCDA Comparison

Compare NOTV & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Inotiv Inc.

NOTV

Inotiv Inc.

HOLD

Current Price

$0.28

Market Cap

10.8M

Sector

Health Care

ML Signal

HOLD

BCDA

BioCardia Inc.

HOLD

Current Price

$1.16

Market Cap

12.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NOTV
BCDA
Founded
1974
N/A
Country
United States
United States
Employees
N/A
21
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.8M
12.9M
IPO Year
1997
N/A

Fundamental Metrics

Financial Performance
Metric
NOTV
BCDA
Price
$0.28
$1.16
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$1.50
$25.00
AVG Volume (30 Days)
981.7K
54.8K
Earning Date
05-11-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
49.64
N/A
EPS
N/A
N/A
Revenue
$547,656,000.00
N/A
Revenue This Year
$5.28
N/A
Revenue Next Year
$5.42
N/A
P/E Ratio
N/A
N/A
Revenue Growth
511.19
N/A
52 Week Low
$0.22
$1.00
52 Week High
$3.31
$3.20

Technical Indicators

Market Signals
Indicator
NOTV
BCDA
Relative Strength Index (RSI) 47.14 45.22
Support Level $0.24 $1.12
Resistance Level $0.41 $1.31
Average True Range (ATR) 0.04 0.07
MACD 0.01 0.00
Stochastic Oscillator 33.14 45.00

Price Performance

Historical Comparison
NOTV
BCDA

About NOTV Inotiv Inc.

Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

Share on Social Networks: